Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05627063 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors
A Phase 1 study of Solid Tumor, sponsored by Abbisko Therapeutics Co.
- Active
- Registry status
- Phase 1
- Development phase
- 169
- Enrollment target
- 20
- Study locations
NCT05627063: Active Phase 1 study of Solid Tumor, sponsored by Abbisko Therapeutics Co.
NCT05627063 is a Phase 1 study of Solid Tumor that is active but no longer recruiting, run by Abbisko Therapeutics Co. The registered enrollment target is 169 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (24% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05627063, a Phase 1 study of Solid Tumor, is active but no longer recruiting, sponsored by Abbisko Therapeutics Co.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 169 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label phase 1 study with expansion. The study will start with a dose escalation of single-agent ABSK121-NX administered in repeated 28-day cycles in patients with advanced solid tumors to evaluate safety and tolerability. The expansion part will investigate oral ABSK121-NX at the recommended dose for expansion (RDE) to further evaluate safety and tolerability among selected tumor types. Preliminary antitumor activity will also be assessed.
Primary Outcome
dose-limiting toxicities (DLTs)
Conditions Studied
Interventions
- DRUG ABSK121-NX
Study Locations (20)
Henan
- The First Affiliated Hospital of Henan University of Science & Technology - Luoyang
- The First Affiliated Hospital of Zhengzhou University - Zhengzhou
Sichuan
- West China School of Medicine/West China Hospital of Sichuan University - Chengdu
- Mianyang Central Hospital - Mianyang
Other
- Fujian Cancer Hospital (Department of Hepatobiliary and Pancreatic Oncology /Phase I Ward) - Fuzhou
- Harbin Medical University Cancer Hospital (Gastroenterology Department 2nd Ward) - Haerbin
California
- UC San Diego Moores Cancer Center - La Jolla
Michigan
- Karmanos Cancer Institute - Detroit
Nevada
- Comprehensive Cancer Centers of Nevada - Las Vegas
Ohio
- Gabrail Cancer Center Research - Canton
Chongqing Municipality
- Chongqing University Cancer Hospital - Chongqing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2023-06-26 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 1 |
What the registry record for NCT05627063 still lists
NCT05627063 is an interventional study that assigns participants to a tested intervention. The registered 169 participants enrollment target is mid-sized for trials with a published cap, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (24% lower).
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which ABSK121-NX is the first listed.
NCT05627063 names 20 study sites across 17 states, led by Henan, Sichuan, Other.
Frequently Asked Questions
What is clinical trial NCT05627063 about?
NCT05627063 is a clinical study titled "A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors". This is an open-label phase 1 study with expansion. The study will start with a dose escalation of single-agent ABSK121-NX administered in repeated 28-day cycles in patients with advanced solid tumors to evaluate safety and tolerability. The expansion part will investigate oral ABSK121-NX at the rec...
What is the current status of trial NCT05627063?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 169 participants. The study started on 2023-06-26. Estimated completion is 2026-06-30.
What conditions does trial NCT05627063 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT05627063?
The interventions under investigation include: ABSK121-NX (DRUG).
Who is sponsoring clinical trial NCT05627063?
This trial is sponsored by Abbisko Therapeutics Co, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05627063 being conducted?
This trial has 20 study locations across California, Michigan, Nevada, Ohio, Chongqing Municipality. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05627063's enrollment target sits among peer trials
169 51st of 196 higher than 146 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06191484 · 169 participants · NA
Risk and Resilience to Suicide Following Late-Life Spousal Bereavement
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI